These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17468964)

  • 1. Rituximab in refractory MuSK antibody myasthenia gravis.
    Thakre M; Inshasi J; Marashi M
    J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 4. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
    Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
    J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase + myasthenia gravis.
    Burusnukul P; Brennan TD; Cupler EJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):85-7. PubMed ID: 21386776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
    Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
    J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-lasting treatment effect of rituximab in MuSK myasthenia.
    Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
    Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
    Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
    Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab.
    Hain B; Jordan K; Deschauer M; Zierz S
    Muscle Nerve; 2006 Apr; 33(4):575-80. PubMed ID: 16323216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MuSK-antibody positive myasthenia gravis: questions from the clinic.
    Sanders DB; Juel VC
    J Neuroimmunol; 2008 Sep; 201-202():85-9. PubMed ID: 18684517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MuSK antibody-positive, seronegative myasthenia gravis in Korea.
    Lee JY; Sung JJ; Cho JY; Oh DH; Kim HJ; Park JH; Lee KW; Choi YC; Vincent A
    J Clin Neurosci; 2006 Apr; 13(3):353-5. PubMed ID: 16546389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
    Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
    Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pure ocular anti-musk myasthenia under no immunosuppressive treatment.
    Zouvelou V; Papathanasiou A; Koros C; Rentzos M; Zambelis T; Stamboulis E
    Muscle Nerve; 2013 Sep; 48(3):464. PubMed ID: 23512700
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts.
    Guptill JT; Sanders DB; Evoli A
    Muscle Nerve; 2011 Jul; 44(1):36-40. PubMed ID: 21674519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
    Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
    Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-MuSK positivity on plasmapheresis liquid in a double seronegative myasthenia gravis patient.
    Renard D; Candon S; Jacob M; Trusson R; Reboul P
    Acta Neurol Belg; 2018 Mar; 118(1):119-120. PubMed ID: 28608313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.